Skip to main content
Top
Published in:

03-01-2024 | Cytostatic Therapy | Peritoneal Surface Malignancy

Cytoreductive Surgery with Bidirectional Intraoperative Chemotherapy (BDIC) Using Intravenous Ifosfamide Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Sarcomatosis: A Retrospective Cohort Study

Authors: Mohammed S. Almasri, MBBS, Hakeam A. Hakeam, MS Pharm, BCPS, Norah S. Alnajashi, MBBS, Lana A. Alzamil, BEpi, Ayman Z. Azzam, MBBS, Tarek M. Amin, MD

Published in: Annals of Surgical Oncology | Issue 4/2024

Login to get access

Abstract

Background

Peritoneal sarcomatosis (PS) is a rare tumor with limited therapeutic options. Bidirectional intraoperative chemotherapy (BDIC) using intravenous ifosfamide and doxorubicin-based hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) is an emerging treatment for peritoneal malignancies.

Patients and Methods

Patients with PS who underwent CRS/BDIC using intravenous ifosfamide and HIPEC from January 2017 to July 2021 were retrospectively analyzed. The last follow-up date was May 2022.

Results

A total of 29 patients were included. Overall survival (OS) rates at 6, 12, 24, and 48 months after CRS/BDIC were 93.1%, 89.2%, 81.4%, and 73.3%, respectively. As of May 2022, 6 patients (20.6%) had died, including four (13.8%) with a proven recurrent tumor and two with incomplete tumor resection [completeness of cytoreduction (CC)-2 or CC-3]. Of the 20 patients (68.9%) with CC-0 or CC-1, 7 had locoregional tumor recurrence without distant metastasis, whereas the other 13 were alive with no evidence of recurrent tumor in May 2022. Disease recurrence rates were 15% at 6 months and 35% at 12, 24, and 48 months after CRS/BDIC. Clavien–Dindo class ≥ IIIa complications developed in 9 patients (31.0%) with no deaths. Leukopenia occurred in 5 patients (17.2%) and thrombocytopenia in 12 patients (41.3%); these hematologic abnormalities resolved. A total of 9 (31.0%) patients developed nephrotoxicity; all recovered except one, who progressed to chronic kidney disease.

Conclusions

CRS/BDIC using intravenous ifosfamide and doxorubicin-based HIPEC is a potentially effective treatment for PS and has an acceptable rate of complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002;94(9):2441–6.CrossRefPubMed Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002;94(9):2441–6.CrossRefPubMed
2.
go back to reference Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.CrossRefPubMed Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.CrossRefPubMed
3.
go back to reference Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88(1):66–74.CrossRefPubMed Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88(1):66–74.CrossRefPubMed
4.
go back to reference Anaya DA, Lahat G, Liu J, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009;249(1):137–42.CrossRefPubMed Anaya DA, Lahat G, Liu J, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009;249(1):137–42.CrossRefPubMed
5.
go back to reference Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363.CrossRefPubMedPubMedCentral Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363.CrossRefPubMedPubMedCentral
6.
go back to reference van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.CrossRefPubMed van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.CrossRefPubMed
7.
go back to reference Wong LCK, Li Z, Fan Q, et al. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis—a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(3):640–8.CrossRefPubMed Wong LCK, Li Z, Fan Q, et al. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis—a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(3):640–8.CrossRefPubMed
8.
go back to reference Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol. 2011;2011:185092.PubMedPubMedCentral Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol. 2011;2011:185092.PubMedPubMedCentral
9.
go back to reference de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47–62.CrossRefPubMedPubMedCentral de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47–62.CrossRefPubMedPubMedCentral
10.
go back to reference Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12(11):1351–60.CrossRefPubMed Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12(11):1351–60.CrossRefPubMed
11.
go back to reference Sugarbaker PH. Long-term survival is possible using cytoreductive surgery plus HIPEC for sarcomatosis—case report of 2 patients. Int J Surg Case Rep. 2019;64:10–4.CrossRefPubMedPubMedCentral Sugarbaker PH. Long-term survival is possible using cytoreductive surgery plus HIPEC for sarcomatosis—case report of 2 patients. Int J Surg Case Rep. 2019;64:10–4.CrossRefPubMedPubMedCentral
12.
go back to reference Sugarbaker P, Ihemelandu C, Bijelic L. Cytoreductive surgery and HIPEC as a treatment option for laparoscopic resection of uterine leiomyosarcoma with morcellation: early results. Ann Surg Oncol. 2016;23(5):1501–7.CrossRefPubMed Sugarbaker P, Ihemelandu C, Bijelic L. Cytoreductive surgery and HIPEC as a treatment option for laparoscopic resection of uterine leiomyosarcoma with morcellation: early results. Ann Surg Oncol. 2016;23(5):1501–7.CrossRefPubMed
13.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
14.
go back to reference Lin X, Davion S, Bertsch EC, Omar I, Nayar R, Laskin WB. Federation Nationale des Centers de Lutte Contre le Cancer grading of soft tissue sarcomas on needle core biopsies using surrogate markers. Hum Pathol. 2016;56:147–54.CrossRefPubMed Lin X, Davion S, Bertsch EC, Omar I, Nayar R, Laskin WB. Federation Nationale des Centers de Lutte Contre le Cancer grading of soft tissue sarcomas on needle core biopsies using surrogate markers. Hum Pathol. 2016;56:147–54.CrossRefPubMed
15.
go back to reference Bhatt A, Yonemura Y, Mehta S, et al. The Pathologic Peritoneal Cancer Index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol. 2020;27(8):2985–96.CrossRefPubMed Bhatt A, Yonemura Y, Mehta S, et al. The Pathologic Peritoneal Cancer Index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol. 2020;27(8):2985–96.CrossRefPubMed
16.
go back to reference Berger Y, Jacoby H, Kaufmann MI, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(4):1103–9.CrossRefPubMed Berger Y, Jacoby H, Kaufmann MI, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(4):1103–9.CrossRefPubMed
17.
go back to reference de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Doukas M, Verhoef C, Burger JWA. The accuracy of the Surgical Peritoneal Cancer Index in patients with peritoneal metastases of colorectal cancer. Dig Surg. 2021;38(3):205–11.CrossRefPubMed de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Doukas M, Verhoef C, Burger JWA. The accuracy of the Surgical Peritoneal Cancer Index in patients with peritoneal metastases of colorectal cancer. Dig Surg. 2021;38(3):205–11.CrossRefPubMed
19.
go back to reference Hakeam H, Ayman A, Waleed AT, Amen T. Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin. Pleura Peritoneum. 2019;4(4):20190025.CrossRefPubMedPubMedCentral Hakeam H, Ayman A, Waleed AT, Amen T. Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin. Pleura Peritoneum. 2019;4(4):20190025.CrossRefPubMedPubMedCentral
20.
go back to reference Baumgartner JM, Ahrendt SA, Pingpank JF, et al. Aggressive locoregional management of recurrent peritoneal sarcomatosis. J Surg Oncol. 2013;107(4):329–34.CrossRefPubMed Baumgartner JM, Ahrendt SA, Pingpank JF, et al. Aggressive locoregional management of recurrent peritoneal sarcomatosis. J Surg Oncol. 2013;107(4):329–34.CrossRefPubMed
21.
go back to reference Diaz-Montes TP, El-Sharkawy F, Lynam S, et al. Efficacy of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the treatment of recurrent uterine sarcoma. Int J Gynecol Cancer. 2018;28(6):1130–7.CrossRefPubMed Diaz-Montes TP, El-Sharkawy F, Lynam S, et al. Efficacy of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the treatment of recurrent uterine sarcoma. Int J Gynecol Cancer. 2018;28(6):1130–7.CrossRefPubMed
22.
go back to reference Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21(4):233–48.CrossRefPubMed Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21(4):233–48.CrossRefPubMed
23.
go back to reference Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol. 2016;7(2):152–9.CrossRefPubMedPubMedCentral Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol. 2016;7(2):152–9.CrossRefPubMedPubMedCentral
24.
go back to reference Moon JY, Baek SW, Ryu H, et al. VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. Medicine (Baltimore). 2017;96(4):e5942.CrossRefPubMedPubMedCentral Moon JY, Baek SW, Ryu H, et al. VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. Medicine (Baltimore). 2017;96(4):e5942.CrossRefPubMedPubMedCentral
25.
go back to reference Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.CrossRefPubMed Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.CrossRefPubMed
26.
go back to reference Hakeam HA, Arab A, Azzam A, Alyahya Z, Eldali AM, Amin T. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cancer Chemother Pharmacol. 2018;81(4):697–704.CrossRefPubMed Hakeam HA, Arab A, Azzam A, Alyahya Z, Eldali AM, Amin T. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cancer Chemother Pharmacol. 2018;81(4):697–704.CrossRefPubMed
27.
go back to reference Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36(10):1486–91.CrossRefPubMed Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36(10):1486–91.CrossRefPubMed
28.
go back to reference Arga M, Oguz A, Pinarli FG, et al. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors. Pediatr Int. 2015;57(3):406–13.CrossRefPubMed Arga M, Oguz A, Pinarli FG, et al. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors. Pediatr Int. 2015;57(3):406–13.CrossRefPubMed
29.
go back to reference Baratti D, Pennacchioli E, Kusamura S, et al. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2010;17(12):3220–8.CrossRefPubMed Baratti D, Pennacchioli E, Kusamura S, et al. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2010;17(12):3220–8.CrossRefPubMed
Metadata
Title
Cytoreductive Surgery with Bidirectional Intraoperative Chemotherapy (BDIC) Using Intravenous Ifosfamide Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Sarcomatosis: A Retrospective Cohort Study
Authors
Mohammed S. Almasri, MBBS
Hakeam A. Hakeam, MS Pharm, BCPS
Norah S. Alnajashi, MBBS
Lana A. Alzamil, BEpi
Ayman Z. Azzam, MBBS
Tarek M. Amin, MD
Publication date
03-01-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14786-5
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now